Country: Canada
Language: English
Source: Health Canada
LACOSAMIDE
ACCORD HEALTHCARE INC
N03AX18
LACOSAMIDE
200MG
TABLET
LACOSAMIDE 200MG
ORAL
15G/50G
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0152810004; AHFS:
APPROVED
2019-06-10
_Product Monograph_ _-ACH-LACOSAMIDE _ _ Page 1 of 42_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ACH-LACOSAMIDE lacosamide tablets Tablets, 50 mg, 100 mg, 150 mg, 200 mg, Oral Antiepileptic ATC Code: N03AX18 Accord Healthcare Inc. 3535 boul. St. Charles, Suite 704 Kirkland, QC, H9H 5B9 Canada Date of Initial Authorization: June 10, 2019 Date of Revision: January 24, 2023 Submission Control Number: 269505 _Product Monograph_ _-ACH-LACOSAMIDE _ _ Page 2 of 42_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, 7.1.1 Pregnant Women 12/2022 7 Warnings and Precautions, 7.1.2 Breast-feeding 12/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS.................................................................................................................. 4 1.1 Pediatrics ............................................................................................................... 4 1.2 Geriatrics ............................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................... 4 4.1 Dosing Considerations ............................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ......................................................... 4 4.4 Administration .................................................................................... Read the complete document